Alvotech Reports Positive Results for Entyvio Biosimilar in Pivotal Pharmacokinetic Study
核心洞察
Alvotech's AVT80, a biosimilar candidate to Entyvio (vedolizumab), met all primary endpoints in a pivotal pharmacokinetic study comparing safety, tolerability, and immunogenicity profiles in healthy adults.
The randomized, double-blind study evaluated a single 108 mg/0.68 mL subcutaneous injection and demonstrated pharmacokinetic similarity for both subcutaneous and intravenous administration routes.
The positive results enable Alvotech to proceed toward regulatory submissions for both AVT16 (intravenous) and AVT80 (subcutaneous) biosimilars targeting the $6.4 billion Entyvio market.
Alvotech announced positive top-line results from a pivotal pharmacokinetic study for AVT80, its biosimilar candidate to Entyvio (vedolizumab), marking a significant milestone in the company's pursuit of regulatory approval for treatments targeting inflammatory bowel diseases. The study met all primary endpoints, positioning the biotechnology company to advance toward regulatory submissions for both intravenous and subcutaneous formulations.
Study Design and Results
The AVT80-GL-P01 study employed a randomized, double-blind, single-dose, parallel-group design with three arms to evaluate AVT80 against Entyvio in healthy adult participants. The trial assessed pharmacokinetics, safety, tolerability, and immunogenicity profiles following administration of a single 108 mg/0.68 mL subcutaneous injection.
According to the company, the study successfully demonstrated pharmacokinetic similarity for both subcutaneous and intravenous routes of administration to Entyvio. Based on regulatory advice, this clinical study is considered pivotal to support the demonstration of clinical similarity for both AVT16 and AVT80.
"We are very pleased with this result, which is an important milestone in the development of our proposed biosimilar to Entyvio, allowing us to proceed towards regulatory submissions," said Joseph McClellan, Chief Operating Officer. "This milestone further underlines the strength of our platform approach to biosimilars development and manufacture, combining a well-designed and executed clinical study with the design of a high-quality manufacturing process and strong analytical capabilities."
Dual Development Strategy
Alvotech is simultaneously developing two biosimilar candidates: AVT16 for intravenous administration and AVT80 for subcutaneous administration. Both products contain vedolizumab, a human monoclonal antibody that targets and binds specifically to the alpha-4-beta-7 protein (搜索). This protein is preferentially expressed on T helper lymphocytes that migrate into the gastrointestinal tract and cause inflammation characteristic of ulcerative colitis (搜索) and Crohn's disease (搜索).
The successful completion of the AVT80-GL-P01 study satisfies the demonstration of pharmacokinetic similarity for both administration routes, streamlining the regulatory pathway for both biosimilar candidates.
Market Opportunity
Entyvio is indicated for treating adult patients with moderate to severe ulcerative colitis (搜索), which causes inflammation and ulcers in the bowel lining, and moderate to severely active Crohn's disease (搜索), which causes inflammation of the digestive tract. The global market for Entyvio represents a substantial opportunity, with combined net revenues worldwide reaching approximately $6.4 billion in 2025, according to Takeda (搜索)'s quarterly results.
Regulatory Status
AVT16 and AVT80 remain investigational products that have not received regulatory approval in any country. The company notes that biosimilarity has not been established by regulatory authorities and is not claimed at this stage. However, the positive pharmacokinetic study results provide the foundation for upcoming regulatory submissions as Alvotech advances its biosimilar development program.